GlassScriptPhysician profile
Walter M Dunn
NPI 1841245800
$4,589.32
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $517 · 2021: $1,406 · 2022: $827 · 2023: $553 · 2024: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,205.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $806.02 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $548.48 | 2019-2024 | Farxiga, Breztri |
| Pfizer INC. | $437.01 | 2019-2024 | |
| Novo Nordisk INC | $432.19 | 2019-2024 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $359.15 | 2019-2022 | |
| Lilly USA, LLC | $251.50 | 2019-2024 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $250.60 | 2019-2022 | |
| Glaxosmithkline, LLC. | $233.33 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Acadia Pharmaceuticals INC | $120.40 | 2021 | |
| Abbott Laboratories | $95.44 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Amgen INC. | $90.48 | 2019-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.10 | 2020-2024 | Xifaxan |
| Boston Scientific Corporation | $63.84 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $57.43 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.09 | 2021-2023 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.